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Introduction: The objective of this study is to detect the correlation between vaginal maturation value (MV) 
and vaginal pH measurement, serum FSH and E2 levels in women without vaginal infection. 
 
Materials And Methods: Fifty women with vasomotor symptoms were enrolled at the present study. All 
women underwent vaginal pH assessment, measurement of serum FSH and E2 levels and vaginal MV 
measurement in addition to routine follow-up. For determination of vaginal MV, pap smear from lateral 
vaginal wall was obtained and evaluated. 
 
Results: In women with atrophic symptoms, the age and vaginal pH levels were significantly higher than 
women without these symptoms. Highly significant correlation between vaginal pH, vaginal MV and serum 
FSH was detected. Similarly highly significant inverse correlation was present between vaginal pH levels 
and vaginal MV. 
 
Discussion: In summary, this study confirms that vaginal pH and MV are similar to FSH in the identification 
of patients who have low estrogen levels or who are menopausal. Methods of deriving vaginal pH and MV 
are simple, practical, quick and economic. As a conclusion, the present study demonstrated that vaginal pH 
measurement and vaginal MV assessment is similar in diagnosis and monitoring of estrogen deficiency in 
women with urogenital atrophic symptoms. 
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VAJİNAL PH, SERUM FSH VE E2 SEVİYELERİNİ ÖN GÖRMEDE VAJİNAL 




Giriş: Bu çalışmanın amacı vajinal enfeksiyonu olmayan kadınlarda vajinal maturasyon değeri (MV) ile 
vajinal pH, serum FSH ve E2 değerleri arasındaki korelasyonu saptamaktır. 
 
Materyal ve Metotlar: Vasomotor semptomları olan 50 kadın çalışmaya dahil edildi. Kadınlara rutin takibe 
ek olarak vajinal pH, vajinal MV, serum FSH ve E2 ölçümleri uygulandı. 
 
Sonuçlar: Atrofik semptomları olan kadınlarda yaş ve vajinal pH değerleri semptomu olmayan kadınlara 
oranla anlamlı olarak daha yüksek bulundu. Vajinal pH, vajinal MV ve serum FSH arasında kuvvetli bir 
korelasyon tespit edildi. Benzer şekilde, vajinal pH değerleriyle vajinal MV arasında da kuvvetli ters 
korelasyon gözlendi. 
 
Tartışma: Bu çalışmanın sonuçları menopozda olan veya düşük serum östrojeni olan kadınların ayırımında 
vajinal pH ve vajinal MV değerlerinin serum FSH ile benzer olduğunu doğrulamaktadır. Vajinal pH ve MV 
ölçümü basit, pratik,hızlı ve ekonomiktir. Vajinal pH ve vajinal MV ölçümünün ürogenital atrofik şikayetleri 
olan kadınlarda östrogen eksikliğinin tanısında ve takibinde benzer olduğu gösterilmiştir. 
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Menopause has great impacts on life-quality of all 
women and is defined as cessation of menstrual 
bleeding for at least 12 months, serum FSH value 
≥ 40 mIU/ml, and serum E2 level < 20 pg/ml. It 
has been known for decades that without vaginal 
infections, vaginal pH is ≤ 4.5 during the 
reproductive years and > 4.5 before menarche and 
after menopause 1. Only methods of deriving 
vaginal pH were not practical, and had low 
sensitivity and specificity due to contamination 
with cervical mucus, blood, or semen 2. Vaginal 
maturation value (MV) of Meisels 3 calculated 
from the ratios of superficial, intermediate and 
parabasal cells in vaginal smears has been used to 
detect vaginal atrophy and estrogen deficiency in 
postmenopausal symptomatic women. MV is a 
useful marker to examine vaginal maturation and 
reveal vaginal estrogen deficiency regardless of 
the presence of inflammation4. After the 
introduction of vaginal pH device, it has been 
proposed that determination of vaginal pH in the 
absence of vaginitis in an outpatient setting might 
be a diagnostic feature of menopause. In this 
study we aimed to detect the correlation of vaginal 
MV with vaginal pH measurement, serum FSH 





Study population: Fifty peri-postmenopausal 
otherwise healthy women attending to our 
menopause outpatient clinic with climacteric 
symptoms for the first time were enrolled at the 
present study. Demograpic characteristics 
including age, gravidy, parity and body mass 
index (BMI) and urogenital atrophic symptoms 
were questioned by the presence of vaginal 
dryness, dyspareunia, pruritus and dysuri. All 
women underwent vaginal pH assessment, 
measurement of serum FSH and E2 levels and 
vaginal MV measurement in addition to routine 
follow-up. Amine test was carried out 
simultaneously with vaginal pH assessment in 
order to rule out vaginal infections and exclude 
false positive pH values. Women who have 
surgical menopause, systemic diseases, positive 
amine test, previous vaginal surgery involving 
more than 1/3 of the vagina, and women with 
history of current or past therapy of estrogen-
progesteron replacement are excluded. 
 
Vaginal pH measurement: Vaginal pH levels are 
measured by Quickvue® Advance pH and Amines 
Test, developed by Quidel® Corporation (San 
Diego, USA). This device is composed of a foil 
wrapped test (contains nitrazine yellow for pH test 
and bromocresol green for amines test), and sterile 
amine controlled cotton swabs. Cotton swabs are 
applied to the lateral vaginal wall, then rubbed 
over the entire surface of the tests. Results are 
interpreted by formation of blue “plus” or 
“minus” sign on each test. Afterwards, nitrazine 
paper is contacted to the vagina for 5 seconds, and 
the color of the paper is compared with a 
colorimetric scale on an enclosed card, and the pH 
value is determined. 
 
Vaginal MV assessment: Cytological evaluation 
was performed by vaginal smears collected from 
the mid-third of the vaginal lateral wall and 
evaluated in our Pathology Department . In a total 
of 100 exfoliation cells, parabasal cells (P), 
intermediary cells (I), and superficial cells (S) 
were counted and results were expressed as the 
maturation value (MV) of Meisels 3. Superficial 
cells were assigned a point value of 1.0, 
intermediate cells were assigned a point value of 
0.5, and parabasal cells were assigned a point 
value of 0. The number of cells in each category 
was multiplied by the point value, and the 3 
results were added to arrive at a maturation value. 
A value of 0 to 49 indicated low estrogen effect, a 
value of 50 to 64 indicated moderate estrogen 
effect, and a value of 65 to 100 indicated high 
estrogen effect. All examinations were interpreted 
by the same cytopathologist without prior 
knowledge of the subjects’ data. 
 
Statistical analysis: In women with negative 
amine test, chi-square test, Pearson correlation test 
and logistic regression test were used where 
appropiate to assess vaginal pH levels and vaginal 
MV with menopausal status and urogenital 
atrophic symptoms. For statistical analysis SPSS 




Out of 50 women enrolled, 2 had positive amine 
test and remaining 48 women were included into 
the statistical analysis. The mean age was 54,7 
years (range 47-70 years), mean body mass index 
was 25,5. Of the 48 women 18 (37,5%) had serum 
FSH levels < 40mIU/ml. The mean FSH value, E2 
value, and MV were 53,3 mIu/ml; 17,4 pg/ml and 
49,1 respectively. The percentage of women with 
pruritus was 18,7% (n=9); dysuri was 27% 
(n=13), vaginal dryness was 64,6% (n=31) and 
dyspareunia was 70,8% (n=34). All of the women 
with urogenital atrophic symptoms had vaginal 
pH values >5.2 (mean value 6,5±0,48), MV< 65 
(mean value 34,7±16,2), serum FSH levels > 40 
mIU/ml and E2 levels < 20 pg/ml. The 
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demographic and hormonal characteristics of the 
women according to the presence of any of the 
questioned urogenital atrophic symptoms are 
listed in Table 1. 
 
In women with atrophic symptoms, the age and 
vaginal pH levels were significantly higher than 
women without these symptoms (p<0,003; 
p<0,001 respectively). In addition, women with 
atrophic symptoms had significantly lower serum 
E2 levels, and vaginal MV (p<0,001; p<0,01 
respectively) (Figure 1). However, serum FSH 
levels were statistically similar between groups 
probably due to high standart deviation values. 
There was no significant difference between 








n=34 (70,8%) n=14 (29,2%) n=48 (100%)
General Features Mean ± SD Mean ± SD Mean ± SD
Age (yrs) 56,4 ± 5,1 ¹ 50,1 ± 4,8¹ 54,7 ± 5,5
Gravidy 3,3 ± 2,5 4,1 ± 2,2 3,5 ± 2,4
Parity 1,8 ± 1,2 2,2 ± 0,8 1,1 ± 3,5
BMI 25,1 ± 3,4 26,4 ± 3,7 25,5 ± 3,5
Hormonal Features Mean ± SD Mean ± SD Mean ± SD
Serum FSH (mIU/ml) 70,1 ± 23,2 12,6 ± 3,7 53,3 ± 32,8
E2 (pg/ml) 11,2 ± 5,4 4 32,2 ± 15,5 4 17,4 ± 13,4
Vaginal Mean ± SD Mean ± SD Mean ± SD
Maturation Value 34,7 ± 16,2 ³ 83,8 ± 9,4³ 49,1 ± 26,7
Parabasal 19,7 ± 27,7 4,6 ± 7,4 15,3 ± 24,5
Intermediate 75,6 ± 26,9 32,8 ± 35,3 63,1 ± 35,2
Superficial 4,7 ± 9,4 62,5 ± 34,1 21,5 ± 33
pH 6,5 ± 0,48 ² 4,6 ± 0,31² 5,9 ± 0,95




Figure 1: A-B) Different examples of atrophic vaginal smear (Pap stain x 100)
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Pearson correlation analysis showed highly 
significant inverse correlation between vaginal 
MV and serum FSH (r=-0,87; p<0.01) (Figure 2). 
Similarly highly significant inverse correlation 
was present between vaginal pH levels and 
vaginal MV (r=-0,9; p<0,01) (Figure 3). 
Calculated correlation was moderate between 
vaginal MV and serum E2 levels (r=0,55; p<0,01). 
MV significantly decreased concomitant with 
increasing serum FSH levels and increasing 
vaginal pH values. On the other hand, the 
decrease in MV only moderately correlated with 
decreasing circulating E2 values. Lineer regression 
analysis was performed and showed significant 
increase of vaginal pH and significant decrease of 
MV with rising serum FSH levels. In the present 
study the positive and negative predictive values 
for vaginal MV < 65 to predict serum FSH levels 





In the present study vaginal MV assessment and 
vaginal pH measurement correlates with serum 
FSH and E2 levels. Accordingly estrogen 
deficiency in women can be detected by simply 
determining MV in vaginal smear specimens as 
well as measuring vaginal pH performed during 
routine gynecologic follow-up. The menopausal 
transition period lead to the development of 
certain signs and symptoms adversely affecting 
the life-quality of most women due to systemic 
estrogen deficiency. Most prominent of these 
symptoms are vasomotor hot flushes, insomnia, 
urogenital atrophy and problems in sexual 
function 5. In spite of the fact that vaginal dryness 
due to atrophic vaginitis is known to be present in 
up to 40% of postmenopausal women 6, the real 
incidence might be even higher since women, 
especially in advanced ages, regard these 
symptoms as age specific. Capewell et al, 
proposed that some clinical characteristics can 
predict the atrophy degree 7. In their study of 120 
postmenopausal women, they found a correlation, 
among the atrophy degree at the vaginal cytology 
and the vaginal dryness at physical examination, 
low parity and physical thinness 7. However, 
Davila et al demonstrated weak correlations 
between symptoms scores and objective measures 
of genital atrophy 8. They concluded that vaginal 
pH is the solid predictor of maturation value and 
may be the most reliable indicator of urogenital 
atrophy 8. In the present study, the strong inverse 
correlation between vaginal pH and MV confirms 
the previous findings. According to the results of 
the present study, MV measurement can aid the 
clinicians to predict serum FSH levels and vaginal 
pH values. MV assessment alone could be a guide 
for the diagnosis and management of a woman 
with urogenital atrophy regardless of the presence 
of atrophic symptoms. 
 
The positive correlation between vaginal pH and 
serum FSH has been demonstrated previously in 
the meta-analysis of 16 reports by Roy et al 9. In 
their study they confirmed that vaginal pH reflects 
circulating estradiol levels 9. Therefore, with the 
     Figure 2: The inverse correlation between serum FSH 
levels and vaginal MV. (r=-0,868; p<0,01) 
Figure 3: The inverse correlation between vaginal pH and
vaginal MV (r=-0,903; p<0,01) 
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use of vaginal pH values, it is possible to monitor 
the introduction dose, change the continuation 
dose and route of therapy in women receiving 
estrogen replacement therapy (ET). In women 
with urogenital atrophic symptoms, who receive 
ERT, elevated vaginal pH decrease to lower levels 
resulting in partially or completely relief of the 
symptoms 9. In a postmenopausal woman who is 
on ET, vaginal pH value of > 4,5 indicates low 
circulating estradiol levels, which suggests the 
need for an adjustment of dose or route of 
hormone therapy 10. However in the present study 
decreasing serum E2 levels were only moderately 
correlated with increasing vaginal pH values and 
decreasing MV. It has been demonstrated 
previously that in some women although serum E2 
levels are sufficient, vaginal atrophy may persist 
11. For them, augmenting oral therapy with topical 
vaginal estrogen may be necessary 12. In the 
present study the demonstrated inverse correlation 
between vaginal pH and MV point out that MV < 
65, similarly, suggests vaginal estrogen deficiency 
although sufficient circulating E2 levels might be 
detected, and administration of ET or adjustments 
in dose or route of ET would be necessary. 
 
In women with vaginitis, vaginal pH measurement 
has increased false positive results due to 
overgrowth of facultatively and obligately 
anaerobic bacteria 13, and is useful only for 
monitoring antimicrobial therapy. Therefore, 
amine test is preferably performed simultaneously 
with the vaginal pH measurement to rule out 
vaginal inflammation even in asymptomatic 
women. Conversely, MV is not adversely affected 
and can be safely used to document estrogen 
deficiency in women with vaginal inflammation. 
 
From previous studies it is known that body mass 
index can influence serum E2 values and 
consecutively vaginal pH 9. In the present study 
body mass index of women without vaginal 
atrophic symptoms was similar to women with 
vaginal atrophy. Therefore body mass index was 
not a confounding factor in the present study. 
 
The positive and negative predictive values should 
be calculated by epidemiologic population-based 
studies. The power of this study is not obviously 
enough to calculate a solid predictive value of 
vaginal pH or MV for menopausal status. On the 
other hand, percentages mentioned reflect the 
population referring to our clinic and might aid 
the clinicians in diagnosis and follow-up. It should 
also be noted that the population included into the 
present study was perimenopausal and early 
postmenopausal women; therefore results 
classified according to urogenital atrophic 
symptoms might not be generalized for older 
women who regard these symptoms as age 
specific. 
 
In the present study we concluded that vaginal 
MV is similar to vaginal pH in the identification 
of patients who have low estrogen levels or who 
are menopausal. In postmenopausal women 
receiving ET, vaginal MV calculation would aid 
the clinicians, in the same manner as vaginal pH, 
to monitor the therapy, change the dose or route of 
administration, or augment the therapy with a 
topical vaginal estrogen. Methods of deriving 
vaginal MV and pH are simple, practical, quick 
and economic. Moreover, MV can be obtained 
simultaneously with Pap smear test, which is a 
part of routine follow-up, does not require 
additional intervention, and easily interpreted at 
office setting. As a conclusion the present study 
demonstrated that vaginal maturation value 
assessment, unlike serum E2 levels, is similar to 
vaginal pH values in diagnosis and management 
of estrogen deficiency in perimenopausal and 
early postmenopausal women with urogenital 
atrophic symptoms regardless of receiving past or 
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